Table II.
BCL2 and MKI67 expression in endometrial polyps (stroma and gland), stratified by polyp size, histologic type and years since menopause.
| Polyp size | Histologic type (polyp) | Years since menopause | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Genes | <2 cm | ≥2 cm | P-valuea | A | H | P-valuea | <9 years | ≥10 years | P-valuea |
| BCL2 G | 2.8±0.4 | 2.6±0.6 | 0.61 | 2.6±0.6 | 2.8±0.3 | 0.41 | 2.6±0.6 | 2.7±0.5 | 0.41 |
| BCL2 S | 2.3±0.6 | 2.7±0.4 | 0.04 | 2.7±0.4 | 2.5±0.6 | 0.30 | 2.5±0.6 | 2.7±0.4 | 0.58 |
| MKI67 G | 1.3±0.5 | 1.5±0.5 | 0.24 | 1.3±0.4 | 1.7±0.4 | 0.04 | 1.5±0.5 | 1.5±0.5 | 0.87 |
| MKI67 S | 1.0±0.3 | 1.0±0.2 | 0.97 | 1.0±0.2 | 1.1±0.3 | 0.23 | 1.0±0.2 | 1.1±0.3 | 0.60 |
aMann-Whitney test. BCL2 and MKI67 expression in endometrial polyps was classified as 1 (weak), 2 (moderate) and 3 (intense). BCL2 G, BCL2 glandular; BCL2 S, BCL2 stromal; MKI67 G, MKI67 glandular; MKI67 S, MKI67 stromal; A, atrophic; H, hyperplasic; MKI67, marker of proliferation Ki-67.